Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631041 | 0.83 | LCK (0.53) | LCKRAB9ANPC1 | |
| SCHEMBL19630738 | 0.76 | LCK (0.51) | LCKRAB9ANPC1MEN1KMT2A | |
| SCHEMBL19630784 | 0.76 | LCK (0.51) | LCKRAB9ANPC1MEN1KMT2A | |
| SCHEMBL19630737 | 0.73 | LCK (0.51) | LCK | |
| SCHEMBL19630788 | 0.72 | LCK (0.52) | LCKRAB9ANPC1MEN1KMT2A | |
| SCHEMBL30189854 | 0.70 | LCK (0.48) | LCKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19783377 | 0.70 | LCK (0.48) | LCKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19630789 | 0.70 | LCK (0.52) | LCKRAB9ANPC1MEN1KMT2A | |
| SCHEMBL28902818 | 0.69 | LCK (0.47) | LCKRAB9ANPC1 | |
| SCHEMBL30231217 | 0.69 | LCK (0.47) | LCKRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |